Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864018 · ClinicalTrials.gov registry record · Phase 1
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
A Phase 1 study of Plasma Cell Myeloma and Amyloidosis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 2
- Study locations
NCT01864018 is a Phase 1 study of Plasma Cell Myeloma and Amyloidosis that has completed, run by Mayo Clinic. The registered enrollment target is 87 participants, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01864018, a Phase 1 study of Plasma Cell Myeloma and Amyloidosis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I/II trial studies the side effects and the best dose of cyclophosphamide when given together with ixazomib citrate and dexamethasone in treating patients with previously untreated symptomatic multiple myeloma or light chain amyloidosis. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with ixazomib citrate and dexamethasone may be a better treatment for multiple myeloma or light chain amyloidosis.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- OTHER Laboratory Biomarker Analysis
- DRUG Dexamethasone
- DRUG Ixazomib Citrate
- OTHER Pharmacological Study
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2013-08-20 |
| Est. Completion | 2023-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01864018
The ClinicalTrials.gov registry entry for NCT01864018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (58% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01864018 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01864018 about?
NCT01864018 is a clinical study titled "Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis". This phase I/II trial studies the side effects and the best dose of cyclophosphamide when given together with ixazomib citrate and dexamethasone in treating patients with previously untreated symptomatic multiple myeloma or light chain amyloidosis. Drugs used in chemotherapy, such as cyclophosphamid...
What is the current status of trial NCT01864018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2013-08-20. Estimated completion is 2023-09-09.
What conditions does trial NCT01864018 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma, Amyloidosis.
What interventions are being tested in trial NCT01864018?
The interventions under investigation include: Cyclophosphamide (DRUG), Laboratory Biomarker Analysis (OTHER), Dexamethasone (DRUG), Ixazomib Citrate (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01864018?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01864018 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
RECRUITING · Phase 1
-
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
ACTIVE NOT RECRUITING · Phase 1
-
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
ACTIVE NOT RECRUITING · Phase 1
-
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
COMPLETED · Phase 1
-
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
COMPLETED · Phase 1
-
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.